Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPC1063 phase 3 induction and maintenance trial in moderate to severe ulcerative colitis
NL-OMON47446Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ozanimod in autoimmune colitis (6 arms), sponsored by Celgene Corporation. Primary endpoints: Clinical remission at Week 10 and Clinical remission at 52 weeks. Started Aug 2016; status: active, not recruiting.
02
Drugs
ozanimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON47446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47446.